AstraZeneca Appoints Dr. Mike Poole to Lead New ‘Virtual’ Neuroscience Innovative Medicines Unit
Tuesday, 7 February 2012
AstraZeneca today announced the appointment of Dr. Mike Poole to lead its newly created virtual Neuroscience Innovative Medicines Unit (iMed) with the responsibility for a portfolio of large and small molecule projects.
Dr. Poole will help AstraZeneca pioneer a new approach to Neuroscience drug discovery and development by recruiting and leading a small team of AstraZeneca scientists who will tap into the most exciting science in the field. The team will be based in Boston (US) and Cambridge (UK), and manage drug discovery and development projects through collaboration with a network of academic and industry partners in these neuroscience hubs and around the globe.
Dr. Menelas Pangalos, Executive Vice President Innovative Medicines, AstraZeneca, said:
“AstraZeneca is deeply committed to Neuroscience research and the discovery and development of new treatments for a full range of neurological diseases including Alzheimer’s, neuropathic pain, depression and Parkinson’s.
“While many companies have exited or scaled back efforts in this high-risk area, we will step up the search for new medicines to help people with neurological and psychiatric diseases. We are confident this new approach will enable us to tap the most exciting science and discoveries that exist in labs around the world.”
Dr. Poole most recently held the position of Chief Medical Officer for Link Medicine. In addition to his training as a medical doctor and neurologist, he has held international roles in the pharmaceutical industry and served as Vice President of the Neuroscience Therapy Area at Wyeth and Pfizer. Dr. Poole also served as Chief Medical Officer at Hypnion, a biotechnology company acquired by Lilly in 2006. He brings broad leadership expertise and an impressive track record across the areas of drug discovery and development, regulatory affairs, academia, and venture-funded biotechnology.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Laura Woodin +1 302 885 1087
Andrea Conners +1 302 885 7652